pharma · Becker Muscular Dystrophy · Muscular Dystrophies · EWTX
Edgewise Therapeutics
Edgewise Therapeutics is a pharma organization headquartered in Boulder, USA. It trades on NYSE under ticker EWTX. Primary therapeutic focus areas include Becker Muscular Dystrophy, Muscular Dystrophies, Hepatic Impairme
1715 38th St., Boulder, CO 80301, US HQ
2017 Founded
154 Employees
Public company Type
EWTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 1715 38th St., Boulder, CO 80301, US
- Founded
- 2017
- Employees
- 154
- Programs
- 15
- Drugs
- 3
- Patents
- 7
Sevasemten Dose 1
Phase 2 · small molecule · Duchenne Muscular Dystrophy
Sevasemten Dose 1 for Duchenne Muscular Dystrophy is a Phase 2 program (small_molecule) at Edgewise Therapeutics with 2 ClinicalTrials.gov record(s).
Internal code EDG-5506-210
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Edgewise Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Duchenne Muscular Dystrophy
- Status
- active
- Trials
- 2